Roger Ulrich, PhD
Dr. Ulrich is currently a Senior Advisor to Frazier Healthcare Partners. In addition, Roger on the Board of Directors of Remedy Pharmaceuticals, Aminex, and is a Scientific Advisor to Mllendo Therapeutics. Previously, Roger was Chief Scientific Officer of Acerta Pharma (acquired by AstraZeneca) and Co-founder and Chief Development Officer of Calistoga Pharmaceuticals (acquired by Gilead). Prior to Calistoga, Roger was Senior Scientific Director with Merck Research Laboratories and Director of Drug Safety Evaluation at Abbott Laboratories. Earlier, Roger was a Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Roger has authored more than 120 publications and is a Fellow of the Academy of Toxicological Sciences. He holds a Ph.D. in Cellular and Molecular Biology from West Virginia University.